Mumps virus as a potential oncolytic agent
AssigneeMayo Foundation for Medical Education and Research
InventorsMark J. Federspiel, Arun Ammayappan, Gennett Pike, Stephen James Russell
Life of this patent
Estimating the term…
Abstract
This document relates to methods and materials for virotherapy. For example, this document provides methods and materials for treating cancer using a recombinant mumps virus as an oncolytic agent.
Claims19
A recombinant mumps virus (MuV) having oncolytic anti-cancer activity, wherein said recombinant MuV comprises nucleic acid selected from the group consisting of nucleic acid encoding a modified V protein comprising a H to Y substitution at amino acid 203 as numbered in SEQ ID NO:
- 4, nucleic acid encoding a modified matrix (M) protein comprising a L to O substitution at amino acid 338 as numbered in SEQ ID NO:6, nucleic acid encoding a modified fusion (F) protein comprising a Y to S substitution at amino acid 430 as numbered in SEQ ID NO:7, and nucleic acid encoding a modified hemagglutinin-neuraminidase (HN) protein comprising a L to I substitution at amino acid 522 as numbered in SEQ ID NO:9.
A method for treating a patient having cancer, the method comprising:
- administering to the patient a recombinant mumps virus (MuV) having oncolytic anticancer activity, wherein said recombinant MuV comprises nucleic acid selected from the group consisting of nucleic acid encoding a modified V protein comprising a H to Y substitution at amino acid 203 as numbered in SEQ ID NO:
- 4, nucleic acid encoding a modified matrix (M) protein comprising a L to O substitution at amino acid 338 as numbered in SEQ ID NO:6, nucleic acid encoding a modified fusion (F) protein comprising a Y to S substitution at amino acid 430 as numbered in SEQ ID NO:7, and nucleic acid encoding a modified hemagglutinin-neuraminidase (HN) protein comprising a L to I substitution at amino acid 522 as numbered in SEQ ID NO:9.
Dependencies are inferred from the claim text.